相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor T Cell Therapy
Julia Ruark et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies
Divyanshu Dubey et al.
NEUROLOGY (2019)
Association Between Immune-Related Adverse Events During Anti-PD-1 Therapy and Tumor Mutational Burden
David Bomze et al.
JAMA ONCOLOGY (2019)
Neurologic Immune-Related Adverse Events Associated with Immune Checkpoint Inhibition
Peter Chei-way Pan et al.
CURRENT ONCOLOGY REPORTS (2019)
Seronegative autoimmune autonomic ganglionopathy from dual immune checkpoint inhibition in a patient with metastatic melanoma
Catherine A. Gao et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Daniel W. Lee et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors
Alvaro Moreira et al.
EUROPEAN JOURNAL OF CANCER (2019)
Immune checkpoint inhibitor induced anti-glutamic acid decarboxylase 65 (Anti-GAD 65) limbic encephalitis responsive to intravenous immunoglobulin and plasma exchange
Matthew Chung et al.
JOURNAL OF NEUROLOGY (2019)
Chimeric antigen receptor T-cell therapy - assessment and management of toxicities
Sattva S. Neelapu et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Vasculitis associated with immune checkpoint inhibitors-a systematic review
Anisha Daxini et al.
CLINICAL RHEUMATOLOGY (2018)
Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management
Christophoros Astaras et al.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS (2018)
Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors
Kristian M. Hargadon et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2018)
Emergence of Myasthenia Gravis with Myositis in a Patient Treated with Pembrolizumab for Thymic Cancer
So-Young Huh et al.
JOURNAL OF CLINICAL NEUROLOGY (2018)
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Neurologic complications of immune checkpoint inhibitors
Avi Fellner et al.
JOURNAL OF NEURO-ONCOLOGY (2018)
Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis
Javid J. Moslehi et al.
LANCET (2018)
Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab
Koichi Sato et al.
LUNG CANCER (2018)
Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'
David T. Teachey et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Jae H. Park et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome
Robert Q. Le et al.
ONCOLOGIST (2018)
CAR T cell immunotherapy for human cancer
Carl H. June et al.
SCIENCE (2018)
Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia
Bianca D. Santomasso et al.
CANCER DISCOVERY (2018)
Chimeric Antigen Receptor T Cell-Mediated Neurotoxicity in Nonhuman Primates
Agne Taraseviciute et al.
CANCER DISCOVERY (2018)
Seronegative antibody-mediated neurology after immune checkpoint inhibitors
Robert Wilson et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2018)
Neuropathology of a Case With Fatal CAR T-Cell-Associated Cerebral Edema
Matthew Torre et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2018)
Pearls & Oy-sters: Pembrolizumab-induced myasthenia gravis
Mohanad Algaeed et al.
NEUROLOGY (2018)
Natalizumab may control immune checkpoint inhibitor-induced limbic encephalitis
Andreas F. Hottinger et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2018)
Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors
D. Makarious et al.
EUROPEAN JOURNAL OF CANCER (2017)
Continued Response to One Dose of Nivolumab Complicated by Myasthenic Crisis and Myositis
Ryan Ying Cong Tan et al.
Journal of Thoracic Oncology (2017)
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis
James Larkin et al.
ONCOLOGIST (2017)
Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis
Hui Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature
Laura C. Cappelli et al.
ARTHRITIS CARE & RESEARCH (2017)
Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells
Juliane Gust et al.
CANCER DISCOVERY (2017)
Neurological Complications Associated With Anti-Programmed Death 1 (PD-1) Antibodies
Justin C. Kao et al.
JAMA NEUROLOGY (2017)
Neurological toxicities associated with immune-checkpoint inhibitors
Mehdi Touat et al.
CURRENT OPINION IN NEUROLOGY (2017)
PD-1 Checkpoint Inhibitor Associated Autoimmune Encephalitis
Stephanie Schneider et al.
CASE REPORTS IN ONCOLOGY (2017)
CTLA4 as Immunological Checkpoint in the Development of Multiple Sclerosis
Lisa Ann Gerdes et al.
ANNALS OF NEUROLOGY (2016)
Myasthenic crisis and polymyositis induced by one dose of nivolumab
Toshihiro Kimura et al.
CANCER SCIENCE (2016)
Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy
Lisa Zimmer et al.
EUROPEAN JOURNAL OF CANCER (2016)
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Rita Nanda et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy
Yongxian Hu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Myasthenia gravis induced by nivolumab therapy in a patient with non-small-cell lung cancer
Pinar Polat et al.
MUSCLE & NERVE (2016)
Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab
K. H. Vincent Lau et al.
MUSCLE & NERVE (2016)
CNS demyelination and enhanced myelin-reactive responses after ipilimumab treatment
Yonghao Cao et al.
NEUROLOGY (2016)
Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis
Krista Dubin et al.
NATURE COMMUNICATIONS (2016)
Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia
David T. Teachey et al.
CANCER DISCOVERY (2016)
Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer
Tanya J. Williams et al.
JAMA NEUROLOGY (2016)
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
Douglas B. Johnson et al.
JAMA ONCOLOGY (2016)
Bilateral Facial Palsy following Ipilimumab Infusion for Melanoma
Ashley L. Altman et al.
OTOLARYNGOLOGY-HEAD AND NECK SURGERY (2015)
Drug-Associated Dermatomyositis Following Ipilimumab Therapy A Novel Immune-Mediated Adverse Event Associated With Cytotoxic T-Lymphocyte Antigen 4 Blockade
Shirwa Sheik Ali et al.
JAMA DERMATOLOGY (2015)
Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma
Edward J. Gettings et al.
MULTIPLE SCLEROSIS JOURNAL (2015)
Current concepts in the diagnosis and management of cytokine release syndrome
Daniel W. Lee et al.
BLOOD (2014)
Targeting the PD1/PD-L1 axis in melanoma: Biological rationale, clinical challenges and opportunities
Barbara Merelli et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2014)
Role of the Programmed Death-1 (PD-1) pathway in regulation of Theiler's murine encephalomyelitis virus-induced demyelinating disease
Sho Takizawa et al.
JOURNAL OF NEUROIMMUNOLOGY (2014)
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Marco L. Davila et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Ipilimumab in patients with melanoma and autoimmune disease
Chrisann Kyi et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia
Renier J. Brentjens et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Anti-CTLA-4 antibody-induced Guillain-Barre syndrome in a melanoma patient
S. Wilgenhof et al.
ANNALS OF ONCOLOGY (2011)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Autoimmune Targets of Heart and Skeletal Muscles in Myasthenia Gravis
Shigeaki Suzuki et al.
ARCHIVES OF NEUROLOGY (2009)
Autoimmune Inflammatory Myopathy after Treatment with Ipilimumab
Gary Hunter et al.
CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES (2009)
PD-1/PD-L1, but not PD-1/PD-L2, interactions regulate the severity of experimental autoimmune encephalomyelitis
Laura L. Carter et al.
JOURNAL OF NEUROIMMUNOLOGY (2007)
Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis
AD Salama et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
分享论文
